TL;DR
This meta-analysis of eight randomized controlled trials (RCTs) demonstrates that Epidermal Growth Factor (EGF) significantly accelerates the healing of diabetic foot ulcers (DFUs) compared to placebo. The findings suggest EGF is a safe and effective treatment, offering a promising therapeutic option for this debilitating condition.
What Problem Does This Paper Address?
Diabetic foot ulcers (DFUs) are a serious and life-threatening complication of diabetes, leading to significant morbidity, mortality, and lower extremity amputations. Despite the prevalence of diabetes and the associated challenges in wound healing, effective treatments for DFUs remain a critical area of research. While growth factors, including EGF, have shown potential, there's been a lack of consensus on their efficacy and safety due to contradictory results in individual studies. This paper aims to resolve this by conducting a comprehensive meta-analysis to compare EGF with placebo in DFU treatment.
Methods
The researchers performed a systematic literature search across multiple databases (Cochrane Library, PubMed, EMBASE, Google Scholar) for studies published between 2009 and 2021. They included randomized controlled trials (RCTs) that compared epidermal growth factor (EGF) with placebo in the treatment of type 1 and type 2 diabetic patients with foot wounds, focusing on complete healing rates. Studies involving combination therapies, those without reported sample sizes, single-arm studies, or non-human studies were excluded. Data extraction included study design, patient characteristics, and treatment duration. The risk of bias was assessed using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale. Statistical analysis involved calculating risk ratios (RRs) with 95% confidence intervals (CIs) and assessing heterogeneity using Cochran's Q and I² statistics.
Datasets
This paper is a meta-analysis and does not introduce new datasets. Instead, it synthesizes data from eight previously published randomized controlled trials (RCTs). The specific details of these individual RCT datasets are presented in Table 1, which outlines characteristics such as country, study design, intervention, type of diabetes, application frequency, duration of treatment, number of patients, age/ulcer location, Wagner grade, complete healing/ulcer duration, and diabetic ulcer duration.
Key Insights and Ideas
- EGF as a Potent Healing Agent: The meta-analysis strongly supports EGF's role in accelerating DFU healing, showing significantly higher complete healing rates compared to placebo across different time points.
- Addressing Contradictory Evidence: By pooling data from multiple RCTs, this study provides a more robust conclusion than individual studies, helping to resolve the previously observed contradictory results regarding EGF's efficacy.
- Safety and Efficacy Profile: The study suggests that EGF is not only effective but also safe, which is crucial for a treatment intended for a chronic and often complex condition like DFU.
- Importance of Meta-Analysis: This work highlights the value of meta-analysis in synthesizing existing research to draw more definitive conclusions and guide clinical practice, especially when individual study results are inconsistent.
Key Results
The meta-analysis included eight RCTs with a total of 620 patients (337 in the EGF group and 283 in the placebo group).
- Four Weeks: EGF achieved a higher complete healing rate than placebo. The risk ratio was 3.04 (95% CI: 0.50, 18.44), with significant heterogeneity (Chi² = 6.46, df = 2, P = 0.04, I² = 69%).
- Eight Weeks: The healing rate for EGF was significantly higher than placebo. The risk ratio was 2.59 (95% CI: 1.42, 4.72), with moderate heterogeneity (Chi² = 7.92, df = 4, P = 0.09, I² = 49%).
- Twelve Weeks: EGF continued to show a higher healing rate. The risk ratio was 1.01 (95% CI: 0.42, 2.46), with significant heterogeneity (Chi² = 8.55, df = 2, P = 0.01, I² = 77%).
- Overall Complete Healing Rate: Across all studies, the EGF group had a complete healing rate of 71%, compared to 58.7% in the placebo group. The overall risk ratio was 1.50 (95% CI: 1.32, 1.71), with low heterogeneity (Chi² = 8.81, df = 7, P = 0.27, I² = 21%).
Limitations and Future Work
The authors acknowledge several limitations:
- Publication Bias: While a funnel plot suggested low publication bias, some potential biases may still exist.
- Study Quality: Some included literature was of poor quality, with a lack of detailed reporting on randomization and blinding, which could affect the reliability of the findings.
- Homogeneous Recruitment: The recruitment of participants across studies was not homogeneous.
- Economic Analysis: Cost-effectiveness data was limited, which is a significant consideration for patients, especially in developing countries.
- Adverse Effects Data: The amount of data on adverse effects was limited, making it difficult to identify the most common side effects of EGF treatment.
Future work suggested includes:
- Well-Designed Clinical Trials: The need for more well-designed clinical trials with longer follow-up periods is emphasized.
- Diverse Populations: Future research should focus on trials involving diverse patient populations.
- Further Examination: More studies are required to further examine the topical EGF therapy in the management of diabetic foot ulcers.
Summary updated